Cargando…
The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy
Changes in the lining of the small intestine following chemotherapy have been extensively studied, although also occurs in the large intestine. The aim of this study was to assess the consequences of Epirubicin-based therapy on goblet cells (GCs) and mucus production on colonic mucosa, immediately a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343623/ https://www.ncbi.nlm.nih.gov/pubmed/34171061 http://dx.doi.org/10.47162/RJME.61.4.14 |
_version_ | 1783734325780414464 |
---|---|
author | Cotoraci, Coralia Adina Sasu, Alciona Onel, Alexandru Fica Mircea Iovănescu, Dana Miuţescu, Eftimie Gharbia, Sami Ciceu, Alina Liliana Herman, Hildegard Hermenean, Anca Oana |
author_facet | Cotoraci, Coralia Adina Sasu, Alciona Onel, Alexandru Fica Mircea Iovănescu, Dana Miuţescu, Eftimie Gharbia, Sami Ciceu, Alina Liliana Herman, Hildegard Hermenean, Anca Oana |
author_sort | Cotoraci, Coralia Adina |
collection | PubMed |
description | Changes in the lining of the small intestine following chemotherapy have been extensively studied, although also occurs in the large intestine. The aim of this study was to assess the consequences of Epirubicin-based therapy on goblet cells (GCs) and mucus production on colonic mucosa, immediately and after short-time of chemotherapy administration to oncohematological patients, by clinical and histopathological analysis. We assessed the mucus production, composition, and distribution by Alcian Blue (pH 2.5)–Periodic Acid–Schiff (PAS) staining, alongside with the immunoexpression of mucin (MUC)2, MUC4 and inflammatory markers in a series of oncohematological patients, immediately and after short-time of Epirubicin-based chemotherapy cumulative therapy cessation. We showed that GCs number decrease slightly at 48 hours, while mucous secretion became mixed (with a few neutral) after three weeks. Overall, the secretion was increased immediately after the Epirubicin administration, due to the activation of inflammatory pathways, assessed by increased immunostaining of tumor necrosis factor-alpha (TNF-α) at 48 hours. The MUC2 and MUC4 showed a decreased immunoexpression at 48 hours after the Epirubicin administration compared to controls and partially restored three weeks after the cessation. Overall, it is highly plausible that all these key players revolve around the chemotherapy-induced mucositis in oncohematological patients and highlights the morphofunctional particularities of the GCs, which further modulates the clinical outcome of the patient. |
format | Online Article Text |
id | pubmed-8343623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest |
record_format | MEDLINE/PubMed |
spelling | pubmed-83436232021-08-18 The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy Cotoraci, Coralia Adina Sasu, Alciona Onel, Alexandru Fica Mircea Iovănescu, Dana Miuţescu, Eftimie Gharbia, Sami Ciceu, Alina Liliana Herman, Hildegard Hermenean, Anca Oana Rom J Morphol Embryol Original Paper Changes in the lining of the small intestine following chemotherapy have been extensively studied, although also occurs in the large intestine. The aim of this study was to assess the consequences of Epirubicin-based therapy on goblet cells (GCs) and mucus production on colonic mucosa, immediately and after short-time of chemotherapy administration to oncohematological patients, by clinical and histopathological analysis. We assessed the mucus production, composition, and distribution by Alcian Blue (pH 2.5)–Periodic Acid–Schiff (PAS) staining, alongside with the immunoexpression of mucin (MUC)2, MUC4 and inflammatory markers in a series of oncohematological patients, immediately and after short-time of Epirubicin-based chemotherapy cumulative therapy cessation. We showed that GCs number decrease slightly at 48 hours, while mucous secretion became mixed (with a few neutral) after three weeks. Overall, the secretion was increased immediately after the Epirubicin administration, due to the activation of inflammatory pathways, assessed by increased immunostaining of tumor necrosis factor-alpha (TNF-α) at 48 hours. The MUC2 and MUC4 showed a decreased immunoexpression at 48 hours after the Epirubicin administration compared to controls and partially restored three weeks after the cessation. Overall, it is highly plausible that all these key players revolve around the chemotherapy-induced mucositis in oncohematological patients and highlights the morphofunctional particularities of the GCs, which further modulates the clinical outcome of the patient. Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest 2020 2021-05-31 /pmc/articles/PMC8343623/ /pubmed/34171061 http://dx.doi.org/10.47162/RJME.61.4.14 Text en Copyright © 2020, Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited. |
spellingShingle | Original Paper Cotoraci, Coralia Adina Sasu, Alciona Onel, Alexandru Fica Mircea Iovănescu, Dana Miuţescu, Eftimie Gharbia, Sami Ciceu, Alina Liliana Herman, Hildegard Hermenean, Anca Oana The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title | The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title_full | The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title_fullStr | The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title_full_unstemmed | The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title_short | The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy |
title_sort | morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under epirubicin-based chemotherapy |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343623/ https://www.ncbi.nlm.nih.gov/pubmed/34171061 http://dx.doi.org/10.47162/RJME.61.4.14 |
work_keys_str_mv | AT cotoracicoraliaadina themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT sasualciona themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT onelalexandruficamircea themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT iovanescudana themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT miutescueftimie themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT gharbiasami themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT ciceualinaliliana themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT hermanhildegard themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT hermeneanancaoana themorphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT cotoracicoraliaadina morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT sasualciona morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT onelalexandruficamircea morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT iovanescudana morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT miutescueftimie morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT gharbiasami morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT ciceualinaliliana morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT hermanhildegard morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy AT hermeneanancaoana morphologicalchangesofthecolonicgobletcellsandmucinprofileinoncohematologicalpatientsunderepirubicinbasedchemotherapy |